

► Spotlight



ALZHEIMER'S ASSOCIATION
AAIC 26

LONDON, UNITED KINGDOM, AND ONLINE
July 12-15, 2026

Visit NACC at the NIH Pavilion at AAIC 2026

NACC is pleased to participate in the Alzheimer's Association International Conference® 2026 (AAIC®), taking place July 12–15, 2026, in London, United Kingdom, and online. As part of the NIH Pavilion, NACC will join fellow NIA- and NIH-supported programs, repositories, studies, and research initiatives that are advancing Alzheimer's disease and related dementias (AD/ADRD) research.

We invite attendees to visit the NIH Pavilion to meet the NACC team, learn about ADRC data resources, and explore the latest developments in the NACC Data Platform and Data Front Door. The Pavilion will also feature mini sessions and opportunities to connect with colleagues from [ACTC](#), the [AD Knowledge Portal](#), [IMPACT-AD](#), [LASI-DAD](#), [LEADS](#), [NCRAD](#), [NIAGADS](#), and [NIA-AD FBS](#). Together, these programs highlight the collaborative infrastructure, data resources, and scientific partnerships that are accelerating discovery across the AD/ADRD research community.

[Register for AAIC](#)

► Recent Research




Distinct Language Impairment in Alzheimer's Disease

Language difficulties are a common feature of Alzheimer's disease, but new research using the NACC dataset suggests that not all language impairments are the same. By analyzing language assessments from more than 5,000 individuals with Alzheimer's disease, researchers found that early-onset Alzheimer's disease is associated with more severe language deficits than late-onset disease. The findings provide new insight into how communication changes across early- and late-onset Alzheimer's disease which may help inform future approaches to diagnosis, care, and language assessment.

[Read More](#)

► Upcoming Events



Webinar: CLARiTi Return of Results and Visual Reads Core Updates

Monday, June 15, 2026, 6-7 pm ET / 3-4 pm PT

[Register Now](#)


Webinar: Navigating the ADRC Portal: Access, Updates, and Reporting

Wednesday, June 17, 2026, 1-2 pm ET / 10-11 am PT

Join NACC for an interactive walkthrough of the ADRC Portal. This webinar is designed to help ADRC teams feel more confident navigating and using the portal in their day-to-day workflows.

[Register Now](#)

► ADRC/CORE Spotlight



Behind the Data Platform

Behind every advancement in the NACC Data Platform is a dedicated team working to support data collection, integration, quality control, and sharing across the ADRC Program. Meet the individuals whose expertise and innovation help make high-quality, multimodal ADRC data accessible to researchers worldwide.

[Meet the NACC Tech Team](#)

► NACC Updates

Get Support from NACC

NACC is continually enhancing our support systems and processes to better serve the ADRC Program and research community. During this transition, you may notice some changes in how support requests are handled. We appreciate your patience and understanding as we implement these improvements. The NACC team remains committed to providing timely assistance.

Visit the NACC Support Page:

Find answers to frequently asked questions, sign up for tech team office hours, or [submit a support request](#).

Join the ADRC Community Forum:

Search the Forum for answers, post questions for NACC staff, and share information with your ADRC colleagues.

Search the NACC Website:

We are always updating the site with more information.

Read the Data Capture and Submission Documentation:

Find UDS forms and technical documentation for the ADRC Portal, data submission, REDCap guidance, etc.

Strategic Data Management Roadmap

New updates include monthly snapshot reports in the ADRC portal and CLARiTi's first data freeze. The Roadmap provides a centralized view of progress across NACC's data and technology initiatives.

[Strategic Data Management Roadmap](#)

► Funding Opportunities

Alzheimer's Disease Strategic Fund: Vascular Contributions to Cognitive Impairment and Dementia 2026—Understanding Mechanisms of Dysfunction (VCID-UMD)

Letter of Intent Due: June 15, 2026, 5 pm ET

Full Application Deadline: September 14, 2026, 5 pm ET

Award Amount: \$150,000 to \$300,000 direct costs; no indirect costs; up to 3 years

This Alzheimer's Association program supports collaborative, high-risk team science investigating the biological mechanisms linking vascular dysfunction to cognitive impairment and dementia. Teams pursuing mechanistic VCID research—or broader ADRC mechanistic questions with a vascular angle—are encouraged to apply.

[VCID-UMD Funding Opportunity](#)

BrightFocus Alzheimer's Disease Research: Postdoctoral Fellowship Award

Full Application Deadline: September 1, 2026, 5 pm

Award Amount: \$200,000 over two years

BrightFocus Foundation invites applications from postdoctoral researchers for its Alzheimer's Disease Research Postdoctoral Fellowship, supporting scientists in their final stages of mentored training toward an independent research career in AD/ADRD. Applicants must be within 5 years of degree conferral. Open to U.S. and international researchers; applications from underrepresented groups are strongly encouraged; no letter of intent required.

[Postdoctoral Award](#)

BrightFocus Alzheimer's Disease Research: Standard Award

Application Deadline: September 1, 2026, 5 pm ET

Award Amount: Up to \$300,000 over three years (\$100,000 per year)

BrightFocus Foundation invites applications for its Alzheimer's Disease Research Standard Award, which funds innovative research in Alzheimer's disease and related dementias. Two tracks are available: Early Career Investigator (within 15 years of degree) and Independent Investigator, which prioritizes interdisciplinary approaches and researchers new to the Alzheimer's field. Open to U.S. and international researchers; no letter of intent required.

[Standard Award](#)

ADDF Neuroimaging and CSF Biomarker Program: Development and Validation of Biomarkers for Alzheimer's Disease and Related Dementias

Letter of Intent Deadline: September 14, 2026, 5 pm ET

Award Amount: Up to \$600,000 based on stage and scope of research

The Alzheimer's Drug Discovery Foundation invites applications to develop and validate neuroimaging and CSF biomarkers for Alzheimer's disease and related dementias, prioritizing targets such as neuroinflammation, synaptic integrity, and TDP-43 across PET, CSF, MRI, and EEG modalities. Open to researchers and clinicians worldwide at academic institutions and nonprofits; awards cover one year of direct costs with follow-on funding potential.

[Apply Now](#)



We Want to Hear from You

Have feedback or news that you'd like included in this newsletter? Email us at naccmail@uw.edu.